SUPPORTING STEMM DIVERSITY AND INCLUSION INITIATIVES FOR WOMEN IN ARTHROPLASTY, SURGERY AND ORTHOPAEDIC ONCOLOGY
With
Associate Professor Claudia Di Bella
Orthopaedic surgeon, Melbourne &
Associate Professor of Surgery
University of Melbourne
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | June 2026
Associate Professor Claudia Di Bella is an academic orthopaedic surgeon based in Melbourne, specialising in orthopaedic oncology and complex joint reconstruction. Originally trained at the world-renowned Rizzoli Orthopaedic Institute (Istituto Ortopedico Rizzoli) in Bologna, Italy, she moved to Australia in 2010 and was awarded Fellowship of the Royal Australasian College of Surgeons in 2013.
She is Associate Professor of Surgery at the University of Melbourne and leads a translational research program focused on tissue engineering and innovative solutions to improve outcomes for patients with musculoskeletal disease, in particular bone sarcomas. Her research has attracted over AUD $6 million in competitive funding, including an NHMRC–MRFF Clinical Investigator Grant, and has resulted in more than 60 peer-reviewed publications, book chapters and numerous national and international presentations. She is passionate about bridging the gap between scientific discovery and meaningful improvements in patient care.
Clinically, A/Prof Di Bella is one of Australia’s few orthopaedic oncology surgeons, managing complex bone and soft tissue tumours and performing high-volume limb salvage surgery and joint reconstruction. Her work combines surgical expertise, innovation and multidisciplinary care for patients facing life-changing diagnoses.
Beyond her clinical and academic roles, Claudia is a strong advocate for diversity, inclusion and representation in medicine. Through national and international leadership roles, including within orthopaedic surgery and sarcoma organisations, she actively mentors the next generation of surgeons and researchers, with a particular commitment to supporting women and underrepresented groups in STEMM and surgical careers.
Source: Supplied
Media access credit: Medical Technology Association of Australia (MTAA)
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
-
Brain cancer Professor mentors Tasmanian researchers
Rosemary Harrup trained in Victoria and Tasmania in Medical Oncology and Clinical Haematology, completing a dual Fellowship in 2001. She is the current Director of Cancer and Blood Services at the Royal Hobart Hospital (RHH), a role she has held since 2009.
Australian Health Journal spoke to Rosemary about her journey in medicine and specifically her work in Clinical Trials in Brain Cancer and the value she placed on her senior clinicians as mentors and how she now mentors others.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
